ArticleTranslational lung cancer research2021
Circulating tumor cells can predict the prognosis of patients with non-small cell lung cancer after resection: a retrospective study.
Article in Translational lung cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Circulating tumour cells in patients with lung cancer universally indicate poor prognosis.European respiratory review : an official journal of the European Respiratory Society · 2022Pooled it
- Consolidated Evidence and New Frontiers of Liquid Biopsy in Lung Cancer: A Narrative Review.Cells · 2026Review
- Circulating tumour cells for guiding antibody‒drug conjugate therapy: Role of artificial intelligence.Clinical and translational medicine · 2026Review
- Evaluation of the Cellsway Microfluidic CTC Enrichment and Identification Platform for CTC Detection in Metastatic NSCLC.Biosensors · 2026Article
- Folate receptor-positive circulating tumor cells as a potential biomarker for breast cancer diagnosis.CytoJournal · 2026Article
- Targeting CTC Heterogeneity: Aptamer-Based Liquid Biopsy Predicts Outcome in Lung Cancer.Cancers · 2025Article
- A comparative study of circulating tumor cell isolation and enumeration technologies in lung cancer.Molecular oncology · 2025Article
- Prognostic Value of the Number of Circulating Tumor Cells in Patients with Metastatic Non-Small Cell Lung Cancer.Micromachines · 2025Article
- Monocytes-to-lymphocytes ratio increases the prognostic value of circulating tumor cells in non-small cell lung cancer: a prospective study.Translational cancer research · 2024Article
- Poor patient outcome correlates with active engulfment of cytokeratin positive CTCs within cancer-associated monocyte population in lung cancer.Clinical & experimental metastasis · 2024Article
- Clinical significance of postoperative folate receptor-positive circulating tumor cells (FR + CTCs) for long-term prognosis in patients with invasive adenocarcinoma (IAC) of the lung.Thoracic cancer · 2024Article
- Advancements in Circulating Tumor Cell Research: Bridging Biology and Clinical Applications.Cancers · 2024Review
- Review
- Targeting circulating tumor cells to prevent metastases.Human cell · 2024Review
- Research progress of CTC, ctDNA, and EVs in cancer liquid biopsy.Frontiers in oncology · 2024Review
- Clinical value of folate receptor-positive circulating tumor cells in patients with esophageal squamous cell carcinomas: a retrospective study.BMC cancer · 2023Article
- Article
- Article
- Review
- Monitoring with circulating tumor cells in the perioperative setting of patients with surgically treated stages I-IIIA NSCLC.Translational lung cancer research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe development of metastasis is the primary cause of death in patients with non-small cell lung cancer (NSCLC). However, identifying those NSCLC patients who will have loco-regional or distant disease recurrence after surgery is still challenging. Circulating tumor cells (CTCs) can accurately reflect the impact of micro-metastasis of tumor cells in circulating blood on patients' treatment and prognosis. The aim of the present study was to explore the value of preoperative CTC concentration in predicting postoperative metastasis and recurrence risk in patients with NSCLC.
methodsThis study enrolled 347 patients with stage I-IIIA NSCLC. The CTCs were isolated using folate receptor (FR) positivity from peripheral blood samples before surgery, and then enriched and analyzed. Patients were divided into two groups for retrospective survival analysis based on the geometric mean of CTC concentration. The primary study endpoint was recurrence-free survival. Spearman's correlation was used to evaluate the relationship between CTC concentration and clinical characteristics of NSCLC patients. A nomogram based on the multivariate Cox regression model was developed to predict recurrence and metastasis in the NSCLC patients. The performance of the nomogram was evaluated using the concordance index, calibration curve, and Hosmer-Lemeshow test.
resultsThe median follow-up time was 38 months. Preoperative CTC concentration was not significantly related to tumor-node-metastasis staging (P>0.05) and was an independent prognostic factor for NSCLC patients [hazard ratio (HR), 5.489; 95% confidence interval (CI): 2.660-11.326, P<0.001]. The nomogram based on preoperative CTC concentration had a concordance index value of 0.82. Validation revealed that the nomogram possessed excellent predictive ability and calibration.
conclusionsPreoperative CTC concentration is an independent and sensitive biomarker of prognosis in patients with NSCLC. Our nomogram based on preoperative CTC concentration is an effective and non-invasive tool for predicting the recurrence and metastasis of NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.